Navigation Links
Many NIH-funded clinical trials go unpublished over 2 years after completion
Date:1/3/2012

In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed biomedical journals, Yale School of Medicine researchers have found that fewer than half of a sample of trials primarily or partially funded by the National Institutes of Health (NIH) were published within 30 months of completing the clinical trial.

These findings appear in the January issue of the British Medical Journal, which focuses on the topic of unpublished evidence.

"When research findings are not disseminated, the scientific process is disrupted and leads to redundant efforts and misconceptions about clinical evidence," said Joseph Ross, M.D., first author of the study and a Yale assistant professor of medicine. "Such inaction undermines both the trial in question and the evidence available in peer-reviewed medical literature. This has far-reaching implications for policy decisions, and even institutional review board assessments of risks and benefits associated with future research studies."

Ross and co-authors performed a cross-sectional analysis of NIH-funded clinical trials registered within ClinicalTrials.gov, a trial registry and results database maintained by the U.S. National Library of Medicine. All trials in the study sample were registered after September 30, 2005 and completed by December 31, 2008, allowing at least 30 months for publication following completion of the trial.

They found that overall fewer than half of NIH-funded trials in the sample were published in a peer-reviewed, MEDLINE-indexed biomedical journal within 30 months of trial completion. They also found that one-third of trials remained unpublished 51 months after completion.

Ross said that there may be many reasons for lack of publication, such as not getting accepted by a journal or not prioritizing the dissemination of research findings. Still, he said, there are alternative methods for providing timely public access to study results, including the results database at ClinicalTrials.gov that was created in response to Federal law.

"Steps must be taken to ensure the timely dissemination of publicly funded research so that data from all those who volunteer are available to inform future research and practice," Ross said.

While this study was focused on trials funded by NIH, Ross said that similar problems with non-publication and delayed publication of research findings have been described among trials funded by the pharmaceutical and medical device industries, as well as by non-profit organizations.

"This suggests that the current culture of research needs to prioritize the timely public dissemination of research findings, ideally via peer-reviewed journals, for research funded by both public and private sources," said Ross. "More work needs to be done to better understand impediments to publication."


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert

Related medicine news :

1. NIH-funded scientists identify potential malaria drug candidates
2. NIH-funded twin study finds occupational chemical exposure may be linked to Parkinsons risk
3. NIH-funded research points to potential therapy for tumor-associated epilepsy
4. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
5. NIH-funded researchers find new ways to confuse blood-seeking mosquitoes
6. NIH-funded study finds new possible risk factor of heart disease
7. NIH-funded study uses new technology to peek deep into the brain
8. In NIH-funded study, researchers uncover step in brain events leading up to addiction
9. NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people
10. University of Mississippi Medical Center to lead in nationwide NIH-funded Alzheimers study
11. NIH-funded scientists find 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... TEXAS (PRWEB) , ... January ... ... Texas-based healthcare and clinical research networking-technology company founded by patient survivors, today ... innovative BlueCloud® business model, networking technologies and patient-inspired initiatives. , Like ...
(Date:1/24/2017)... ... 23, 2017 , ... United Nations Foundation President and CEO ... City Policy, also known as the Global Gag Rule, last enacted in 2001. ... non-governmental organizations from receiving any U.S. foreign assistance for family planning if they ...
(Date:1/24/2017)... , ... January 23, 2017 , ... ... of a new plugin that allows sleep centers to automatically connect and initialize ... (SDI)—is a thin client browser plugin is quickly installed on first use and ...
(Date:1/23/2017)... ... January 23, 2017 , ... Ultimate Medical ... Education Summit to be held March 23-25, 2017 in Tampa, and reminded educators ... , The keynote speakers include Dr. Michelle R. Weise, executive director of the ...
(Date:1/23/2017)... Grants Pass, OR (PRWEB) , ... January 23, 2017 , ... ... disease, took to the air to educate listeners about the benefits of making new ... in the U.S.,” Kleyne said, “it’s appropriate that we expect water infrastructure to become ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted for $3,702.2 ... grow at a CAGR of 6.0% during 2016-2022. The ... in the global market between the two types in ... segment accounted for the highest share in the global ... catheter market is witnessing high growth rate, due to ...
(Date:1/24/2017)... CHICAGO , January 23, 2017 ... solutions for life sciences, announces agClinical 3.3, the latest ... release further enables life science organizations to confidently and ... monitoring and better manage the electronic trial master file ... ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES announced ... to develop and commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) ... Korean pharmaceutical company. nuc -Gemcitabine ... against surface nucleolin found on many cancer cells, ... ADCs (antibody drug conjugates) or SMDCs (small molecule ...
Breaking Medicine Technology: